» Articles » PMID: 22851646

Comparative Oncogenomics Implicates the Neurofibromin 1 Gene (NF1) As a Breast Cancer Driver

Overview
Journal Genetics
Specialty Genetics
Date 2012 Aug 2
PMID 22851646
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Identifying genomic alterations driving breast cancer is complicated by tumor diversity and genetic heterogeneity. Relevant mouse models are powerful for untangling this problem because such heterogeneity can be controlled. Inbred Chaos3 mice exhibit high levels of genomic instability leading to mammary tumors that have tumor gene expression profiles closely resembling mature human mammary luminal cell signatures. We genomically characterized mammary adenocarcinomas from these mice to identify cancer-causing genomic events that overlap common alterations in human breast cancer. Chaos3 tumors underwent recurrent copy number alterations (CNAs), particularly deletion of the RAS inhibitor Neurofibromin 1 (Nf1) in nearly all cases. These overlap with human CNAs including NF1, which is deleted or mutated in 27.7% of all breast carcinomas. Chaos3 mammary tumor cells exhibit RAS hyperactivation and increased sensitivity to RAS pathway inhibitors. These results indicate that spontaneous NF1 loss can drive breast cancer. This should be informative for treatment of the significant fraction of patients whose tumors bear NF1 mutations.

Citing Articles

Aggressive Serous Carcinomas of the Female Reproductive Tract: Cancer-Prone Cell States and Genetic Drivers.

Phuong D, Pirtz M, Ralston C, Cosgrove B, Schimenti J, Flesken-Nikitin A Cancers (Basel). 2025; 17(4).

PMID: 40002199 PMC: 11852459. DOI: 10.3390/cancers17040604.


Association of pituitary neuroendocrine tumors and neurofibromatosis type 1: assessing causation versus coincidence. Case report.

Aguilar-Soto M, Zuarth-Vazquez J, Leyva-Figueroa L, Zarco-Avila K, Gamboa-Dominguez A, Eguiluz-Melendez A Front Endocrinol (Lausanne). 2025; 16:1483305.

PMID: 39968302 PMC: 11832379. DOI: 10.3389/fendo.2025.1483305.


Genomic Alterations Correlated to Trastuzumab Resistance and Clinical Outcomes in HER2+/HR- Breast Cancers of Patients Living in Northwestern China.

Ma G, Huo B, Shen Y, Zhu X, Cheng C, Li W J Cancer. 2024; 15(14):4467-4476.

PMID: 39006074 PMC: 11242333. DOI: 10.7150/jca.84832.


Variation Analysis in Premenopausal and Postmenopausal Breast Cancer Cases.

Erdogdu I, Orenay-Boyacioglu S, Boyacioglu O, Gurel D, Akdeniz N, Meteoglu I J Pers Med. 2024; 14(4).

PMID: 38673061 PMC: 11051104. DOI: 10.3390/jpm14040434.


NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.

House R, Tovar E, Redlon L, Essenburg C, Dischinger P, Ellis A Mol Metab. 2024; 80:101876.

PMID: 38216123 PMC: 10844973. DOI: 10.1016/j.molmet.2024.101876.


References
1.
Greenman C, Stephens P, Smith R, Dalgliesh G, Hunter C, Bignell G . Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMC: 2712719. DOI: 10.1038/nature05610. View

2.
Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

3.
Shima N, Alcaraz A, Liachko I, Buske T, Andrews C, Munroe R . A viable allele of Mcm4 causes chromosome instability and mammary adenocarcinomas in mice. Nat Genet. 2006; 39(1):93-8. DOI: 10.1038/ng1936. View

4.
Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K . Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-75. PMC: 2694412. DOI: 10.1038/nature07423. View

5.
Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D . NF1 inactivation in adult acute myelogenous leukemia. Clin Cancer Res. 2010; 16(16):4135-47. PMC: 2921448. DOI: 10.1158/1078-0432.CCR-09-2639. View